Grünenthal USA Inc.
Grünenthal USA has been named one of the 2017 Best Places to Work in New Jersey.
Grünenthal USA Inc.
Partner in Pain Management
Grünenthal USA is a subsidiary of Grünenthal GmbH, an independent, family-owned pharmaceutical company specializing in pain management.
Grünenthal USA partners with other leading pharmaceutical companies to deliver innovative products to patients living with pain.
Address:
Grünenthal USA, Inc.
360 Mount Kemble Avenue
Morristown, NJ 07960
908-306-0024 (phone)
908-306-1631 (fax)
Commercial footprint in the US
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US
Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.
Grünenthal focusses on developing new therapies/medicines for patients. In order to make these therapies/medicines available to patients, Grünenthal is conducting rigorous clinical trials to assess the safety and efficacy of the investigational therapies/medicines, which if proven, will enable the necessary approvals from regulatory authorities. This process will allow patients to have broad access to these medicines. We encourage patients who want access to our investigational therapies/medicines to participate in our clinical trial programs. Given the investigational status of our compounds in clinical development, we currently do not grant expanded access.
